In the final weeks of 2018, the U.S. Food and Drug Administration (FDA) announced three approvals of anticancer therapeutics. These decisions brought the total number of new anticancer therapeutics approved …Read More
In 2018, we witnessed significant momentum in several hot areas of cancer research, including immunotherapy and precision medicine. Researchers have amassed exponential amounts of knowledge in these areas of scientific inquiry in recent years, and 2018 saw many of these gains culminate into innovative treatments for cancer patients.Read More
The past two weeks have seen a flurry of U.S. Food and Drug Administration (FDA) approvals of new treatments for acute myeloid leukemia (AML). On Nov. 21, 2018, the FDA approved both glasdegib (Daurismo) and venetoclax (Venclexta) for treating patients with newly diagnosed AML who are age 75 or older, or who have chronic health conditions or diseases that prevent them being treated with the standard intensive chemotherapy. A week later, on Nov. 28, 2018, the agency approved gilteritinib (Xospata) for treating patients whose AML tests positive for a mutation in the FLT3 gene.Read More
Radiotherapy is a mainstay of cancer treatment. In recent years, improved technology has allowed many cancer patients to receive more targeted doses of radiation, which can improve efficacy and spare …Read More
On Monday, the U.S. Food and Drug Administration (FDA) announced the highly anticipated approval of the molecularly targeted therapeutic larotrectinib (Vitrakvi) for use based on whether a patient’s tumor tests positive for a specific genetic biomarker and not where in the body the tumor originated.Read More
During the early part of November, we saw the U.S. Food and Drug Administration (FDA) approve a new molecularly targeted therapeutic, lorlatinib (Lorbrena), and expand the use of the immunotherapeutic pembrolizumab (Keytruda). These new approvals, which are for the treatment of certain patients with lung cancer and liver cancer, respectively, highlight that progress in the fields of precision medicine and immunotherapy is continuing unabated.Read More
Cancer patient advocates take on many roles in their communities. They may go out to churches to promote the benefits of cancer screening, lead patient and survivor support groups, or offer a patient’s perspective on review panels that evaluate research grants. Many times, an experience with cancer pushes people to accept advocacy roles to fill some unmet need or simply to give back.
All of these efforts were on display at this year’s American Association for Cancer Research Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved in New Orleans Nov. 2-5. Opening the conference, 10 patient survivors and caregivers of various ethnicities and types of cancers took to the stage to describe how cancer has changed them and what cancer research has given them personally.Read More
In the 1970s television series The Six Million Dollar Man, the narrator says of severely injured astronaut Steve Austin: “We can rebuild him. We have the technology. We can make him better than he was. Better, stronger, faster.” The narrator was referring to “bionic” technologies that provided higher visual acuity, stunning strength, and the ability to run at speeds greater than 60 miles per hour.
Over the past few years, cancer immunologists have achieved a comparable feat. They have taken T cells—the immune cells capable of destroying infectious agents, foreign cells, and cancers—and rebuilt them to be better than they were, better at recognizing and killing cancer cells.Read More
On Friday, Margaret Foti, PhD, MD (hc), chief executive officer of the American Association for Cancer Research, was honored with the 2018 European Society for Medical Oncology (ESMO) Women for Oncology Award for her role in supporting the career development of women in oncology.Read More
In the midst of Breast Cancer Awareness Month, the US. Food and Drug Administration (FDA) provided good news for the breast cancer community this week when it approved a new breast cancer therapeutic called talazoparib (Talzenna), which targets ADP-ribose polymerase (PARP) proteins. They also approved a test to identify those patients eligible to receive talazoparib: patients with metastatic or locally advanced, HER2-negative breast cancer who have an inherited, cancer-associated BRCA1 or BRCA2 (BRCA1/2) mutation.Read More